SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics filed DEFA14A definitive additional proxy…

Outlook Therapeutics, Inc. · DEFA14A filed Jun 1, 2026 at 17:00 ET

At the news

BEARISHIMPACT 6/10

DEFA14A filed Jun 1, 2026 at 17:00 ET

Outlook Therapeutics filed DEFA14A definitive additional proxy materials for its July 16, 2026 Special Meeting. The board recommends voting FOR: (1a) issuance of up to 16,129,033 shares underlying Private Placement Warrants and up to 2,258,064 shares underlying Placement Agent Warrants from an April 2026 registered direct offering; (1b) issuance of up to 2,142,854 shares underlying previously issued common warrants; (2) increasing authorized common shares from 260M to 600M; and (3) a reverse stock split at a ratio between 1:10 and 1:50 at the board's discretion. The massive authorized share increase and reverse split authorization signal the company is preparing for significant future dilution and potential Nasdaq compliance needs.

  • Special Meeting scheduled for July 16, 2026; vote by July 15, 2026
  • Proposal 1a: Approve issuance of up to 16,129,033 shares underlying Private Placement Warrants and up to 2,258,064 shares underlying Placement Agent Warrants from April 2026 offering
  • Proposal 1b: Approve issuance of up to 2,142,854 shares underlying previously issued common warrants
  • Proposal 2: Increase authorized common shares from 260,000,000 to 600,000,000 (a 130.8% increase)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access